The consensus among analysts is that Capricor Therapeutics, Inc. (CAPR) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 2 have rated it as a Hold, with 2 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.34.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) trade information

Despite being -2.42% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Jun 25 when the CAPR stock price touched $5.24-7 or saw a rise of 7.82%. Year-to-date, Capricor Therapeutics, Inc. shares have moved 277.34%, while the 5-day performance has seen it change -2.23%. Over the past 30 days, the shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have changed -8.17%. Short interest in the company has seen 274.19 Million shares shorted with days to cover at 46.16.

Wall Street analysts have a consensus price target for the stock at $10.5, which means that the shares’ value could jump 117.39% from current levels. The projected low price target is $9 while the price target rests at a high of $12. In that case, then, we find that the current price level is +148.45% off the targeted high while a plunge would see the stock lose 86.34% from current levels.

Capricor Therapeutics, Inc. (CAPR) estimates and forecasts

Figures show that Capricor Therapeutics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +302.5% over the past 6 months, with this year growth rate of -29.13%, compared to 3.1% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 42.4% and 34.9% for the next quarter. Revenue growth from the last financial year stood is estimated to be -46.3%.

1 analysts offering their estimates for the company have set an average revenue estimate of $210Million for the current quarter. 1 have an estimated revenue figure of $210Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $410Million and $142Million respectively for this quarter and the next, and analysts expect sales will grow by -48.8% for the current quarter and 47.9% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +17.3% over the past 5 years. Earnings growth for 2020 is a modest +60.1% while over the next 5 years, the company’s earnings are expected to increase by 0%.